Recurrent Andor Metastatic | List of Frontiers open access articles

Review

Published on 09 May 2017

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

in Head and Neck Cancer

Athanassios Argiris
Kevin J. Harrington
Makoto Tahara
Jeltje Schulten
Pauline Chomette
Ana Ferreira Castro
Lisa Licitra

Frontiers in Oncology

doi 10.3389/fonc.2017.00072

29,806 views
154 citations

Original Research

Published on 02 Aug 2021

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis

in Cancer Immunity and Immunotherapy

Ze-Jiang Zhan
Wen-Yu Yao
Fang Zhang
Wen-Ze Qiu
Kai- Liao
Jian-Hui Feng
Jin-Yun Tan
Hui Liu
Tai-Ze Yuan
Rong-Hui Zheng

Frontiers in Immunology

doi 10.3389/fimmu.2021.719650

8,782 views
6 citations

Mini Review

Published on 13 Feb 2019

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

in Head and Neck Cancer

Esma Saada-Bouzid
Christophe Le Tourneau

Frontiers in Oncology

doi 10.3389/fonc.2019.00074

5,835 views
22 citations

Clinical Trial

Published on 07 Feb 2024

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial

in Head and Neck Cancer

Anna Brandt
Christoph Schultheiss
Konrad Klinghammer
Philippe Schafhausen
Chia-Jung Busch
Markus Blaurock
Axel Hinke
Mareike Tometten
Andreas Dietz
Urs Müller-Richter

Frontiers in Oncology

doi 10.3389/fonc.2024.1283266

5,300 views
10 citations

Original Research

Published on 27 Oct 2021

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients

in Head and Neck Cancer

Hélène Carinato
Mickaël Burgy
Régine Ferry
Cathie Fischbach
Michal Kalish
Sébastien Guihard
Youssef Brahimi
Henri Flesch
Guy Bronner
Philippe Schultz

Frontiers in Oncology

doi 10.3389/fonc.2021.714551

11,164 views
14 citations

Original Research

Published on 07 Oct 2020

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma

in Head and Neck Cancer

Yuri Ueda
Tomohiro Enokida
Susumu Okano
Takao Fujisawa
Kazue Ito
Makoto Tahara

Frontiers in Oncology

doi 10.3389/fonc.2020.571304

6,327 views
13 citations

Review

Published on 21 Aug 2019

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions

in Head and Neck Cancer

Joël Guigay
Makoto Tahara
Lisa Licitra
Ulrich Keilholz
Signe Friesland
Pauline Witzler
Ricard Mesía

Frontiers in Oncology

doi 10.3389/fonc.2019.00668

13,397 views
44 citations

Original Research

Published on 20 Sep 2022

Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting

in Gynecological Oncology

Fernando Cotait Maluf
Graziela Dal Molin Zibetti
Eduardo Paulino
Andreia Cristina de Melo
Douglas Racy
Robson Ferrigno
Pedro Luiz Serrano Uson Junior
Reitan Ribeiro
Renato Moretti
Jose Carlos Sadalla

Frontiers in Oncology

doi 10.3389/fonc.2022.928568

6,240 views
4 citations

Review

Published on 31 Aug 2016

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck

in Head and Neck Cancer

Petr Szturz
Jan B. Vermorken

Frontiers in Oncology

doi 10.3389/fonc.2016.00199

44,242 views
104 citations

Original Research

Published on 04 Jul 2022

Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck

in Head and Neck Cancer

Tetsuro Wakasugi
Thi Nga Nguyen
Shoko Takeuchi
Jun-ichi Ohkubo
Hideaki Suzuki

Frontiers in Oncology

doi 10.3389/fonc.2022.876193

2,565 views
3 citations

Review

Published on 06 May 2020

Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity

in Head and Neck Cancer

Petr Szturz
Carl Van Laer
Christian Simon
Dirk Van Gestel
Jean Bourhis
Jan B. Vermorken

Frontiers in Oncology

doi 10.3389/fonc.2020.00688

14,062 views
34 citations

Original Research

Published on 28 Apr 2020

MicroRNA-381-3p Functions as a Dual Suppressor of Apoptosis and Necroptosis and Promotes Proliferation of Renal Cancer Cells

in Molecular and Cellular Pathology

Cong Zhao
Yifei Zhou
Qiao Ran
Ying Yao
Haoran Zhang
Jie Ju
Tao Yang
Wei Zhang
Xiaoliang Yu
Sudan He

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2020.00290

6,882 views
43 citations

Clinical Trial

Published on 19 Mar 2019

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

in Head and Neck Cancer

Emmanuel Seront
Sandra Schmitz
Matthias Papier
Aline van Maanen
Stéphanie Henry
Christophe Lonchay
Sylvie Rottey
Gabrielle van Caloen
Jean-Pascal Machiels

Frontiers in Oncology

doi 10.3389/fonc.2019.00155

3,750 views
22 citations

Articles

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions

Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck

Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck

Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity

MicroRNA-381-3p Functions as a Dual Suppressor of Apoptosis and Necroptosis and Promotes Proliferation of Renal Cancer Cells

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck